Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma

STK11 has been recently reported to be associated with primary resistance to PD-(L1)1 axis inhibitors. We report a case of near-complete response to first-line pembrolizumab/platinum-doublet regimen in a patient with KRAS/STK11-mutant advanced lung adenocarcinoma. Our case highlights that STK11 should not be used to select patients for PD(L)-1 blockade therapy, especially with used together with chemotherapy until further prospective validation and clarification of interactions with other biomarkers such as TMB and PD-L1. (C) 2021 Elsevier Inc. All rights reserved.

Automated summary

We report a case of near-complete response to first-line pembrolizumab/platinum-doublet regimen in a patient with KRAS/STK11-mutant advanced lung adenocarcinoma. The study highlights that STK11 should not be used to select patients for PD(L)-1 blockade therapy until further prospective validation and clarification of interactions with other biomarkers such as TMB and PD-L1.